Show simple item record

dc.contributor.authorDiego González, Lara 
dc.contributor.authorFernández Carrera, Andrea
dc.contributor.authorIgea Fernández, Ana
dc.contributor.authorMartínez Pérez, Amparo
dc.contributor.authorReal Oliveira, M. Elisabete C. D.
dc.contributor.authorGomes, Andreia C.
dc.contributor.authorGuerra, Carmen
dc.contributor.authorBarbacid, Mariano
dc.contributor.authorGonzález Fernández, Maria Africa 
dc.contributor.authorSimón Vázquez, Rosana 
dc.date.accessioned2022-07-06T12:03:41Z
dc.date.available2022-07-06T12:03:41Z
dc.date.issued2022-06-24
dc.identifier.citationCancers, 14(13): 3102 (2022)spa
dc.identifier.issn20726694
dc.identifier.urihttp://hdl.handle.net/11093/3664
dc.description.abstractPancreatic cancer evades most of the current therapies and there is an urgent need for new treatments that could efficiently eliminate this aggressive tumor, such as the blocking of routes driving cell proliferation. In this work, we propose the use of small interfering RNA (siRNA) to inhibit the combined expression of FOSL-1 and YAP, two signaling proteins related with tumor cell proliferation and survival. To improve the efficacy of cell transfection, DODAB:MO (1:2) liposomes were used as siRNA nanocarriers, forming a complex denominated siRNA-lipoplexes. Liposomes and lipoplexes (carrying two siRNA for each targeted protein, or the combination of four siRNAs) were physico-chemically and biologically characterized. They showed very good biocompatibility and stability. The efficient targeting of FOSL-1 and YAP expression at both mRNA and protein levels was first proved in vitro using mouse pancreatic tumoral cell lines (KRASG12V and p53 knockout), followed by in vivo studies using subcutaneous allografts on mice. The peri-tumoral injection of lipoplexes lead to a significant decrease in the tumor growth in both Athymic Nude-Foxn1nu and C57BL/6 mice, mainly in those receiving the combination of four siRNAs, targeting both YAP and FOSL-1. These results open a new perspective to overcome the fast tumor progression in pancreatic cancer.en
dc.description.sponsorshipXunta de Galicia | Ref. ED431C 2020/02spa
dc.description.sponsorshipXunta de Galicia | Ref. ED431G2019/06spa
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades | Ref. RTI2018-094664-B-I00spa
dc.description.sponsorshipMinisterio de Economía, Industria y Competitividad | Ref. BIO2017-84974-Rspa
dc.language.isoengspa
dc.publisherCancersspa
dc.relationinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-094664-B-I00/ES
dc.relationinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BIO2017-84974-R/ES
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleCombined inhibition of FOSL-1 and YAP using siRNA-lipoplexes reduces the growth of pancreatic tumoren
dc.typearticlespa
dc.rights.accessRightsopenAccessspa
dc.identifier.doi10.3390/cancers14133102
dc.identifier.editorhttps://www.mdpi.com/2072-6694/14/13/3102spa
dc.publisher.departamentoBioquímica, xenética e inmunoloxíaspa
dc.publisher.grupoinvestigacionInmunoloxíaspa
dc.subject.unesco2410.07 Genética Humanaspa
dc.subject.unesco3207.03 Carcinogénesisspa
dc.subject.unesco2412 Inmunologíaspa
dc.date.updated2022-07-06T10:48:41Z
dc.computerCitationpub_title=Cancers|volume=14|journal_number=13|start_pag=3102|end_pag=spa


Files in this item

[PDF]

    Show simple item record

    Attribution 4.0 International
    Except where otherwise noted, this item's license is described as Attribution 4.0 International